Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | STAT3 | P40763 | 1/20 | 0.48 |
| ▸ | NOS2 | P35228 | 4/20 | 0.47 |
| ▸ | NOS1 | P29475 | 3/20 | 0.47 |
| ▸ | NOS3 | P29474 | 1/20 | 0.47 |
| ▸ | GPR174 | Q9BXC1 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11845003 | 0.92 | MAPT (0.64) | MAPTSMN1; SMN2LMNAALDH1A1POLB | |
| SCHEMBL22605777 | 0.88 | MAPK1 (0.48) | MAPTSMN1; SMN2LMNAALDH1A1POLB | |
| SCHEMBL4636292 | 0.87 | MAPT (0.62) | MAPTSMN1; SMN2LMNAALDH1A1POLB | |
| SCHEMBL4637044 | 0.86 | MAPT (0.61) | MAPTSMN1; SMN2LMNAALDH1A1POLB | |
| SCHEMBL18546959 | 0.86 | ALDH1A1 (0.53) | MAPTSMN1; SMN2LMNAALDH1A1POLB | |
| SCHEMBL4670055 | 0.85 | SMN1; SMN2 (0.59) | MAPTSMN1; SMN2LMNAALDH1A1POLB | |
| SCHEMBL4635816 | 0.84 | NOS2 (0.59) | MAPTSMN1; SMN2LMNAALDH1A1POLB | |
| SCHEMBL605250 | 0.83 | LMNA (0.55) | MAPTSMN1; SMN2LMNAALDH1A1MAPK1 | |
| SCHEMBL4910166 | 0.82 | LMNA (0.63) | MAPTSMN1; SMN2LMNAALDH1A1POLB | |
| SCHEMBL10264104 | 0.82 | LMNA (0.53) | MAPTSMN1; SMN2LMNAALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2004182-B1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LTD (GB) | 2013-05-08 | — | — | EP | disclosed |
| EP-2004182-B1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LTD (GB) | 2013-05-08 | — | — | EP | disclosed |
| US-20120316202-A1 | Compounds which have activity at M1 receptor and their uses in medicine | GLAXO GROUP LIMITED | 2012-12-13 | — | — | US | disclosed |
| US-8288413-B2 | Benzimidazolones which have activity at M1 receptor | GLAXO GROUP LIMITED (GB) | 2012-10-16 | — | — | US | disclosed |
| US-8288413-B2 | Benzimidazolones which have activity at M1 receptor | GLAXO GROUP LIMITED (GB) | 2012-10-16 | — | — | US | disclosed |
| US-20120041028-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED | 2012-02-16 | — | — | US | disclosed |
| US-20100280071-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| US-20100280071-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| US-20100280071-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| EP-2004182-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-12-24 | — | — | EP | disclosed |
| US-20080306112-A1 | Benzimidazolones Which Have Activity at M1 Receptor | GLAXO GROUP LIMITED (GB) | 2008-12-11 | — | — | US | disclosed |
| US-20080306112-A1 | Benzimidazolones Which Have Activity at M1 Receptor | GLAXO GROUP LIMITED (GB) | 2008-12-11 | — | — | US | disclosed |
| EP-1937670-A1 | BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT M1 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007107565-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007107565-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007036711-A1 | BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT Ml RECEPTOR | GLAXO GROUP LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
| WO-2007036711-A1 | BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT Ml RECEPTOR | GLAXO GROUP LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041028-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | CHRM1, CHRM2, CHRM4 | MAPT 584/4885SMN1; SMN2 1956/4885LMNA 2901/4885 |
| US-20100280071-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | CHRM1, CHRM2, CHRM4 | MAPT 584/4885SMN1; SMN2 1956/4885LMNA 2901/4885 |
| US-20120316202-A1 | Compounds which have activity at M1 receptor and their uses in medicine | CHRM1, CHRM2, CHRM5 | MAPT 502/4885SMN1; SMN2 1721/4885LMNA 3164/4885 |
| US-20080306112-A1 | Benzimidazolones Which Have Activity at M1 Receptor | CHRM1, CHRM2, CHRM4 | MAPT 2221/4885SMN1; SMN2 3320/4885LMNA 3257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.